Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“Major FDA news today for early-stage HER2+ breast cancer. T-DXd approved for two separate indications: neoadjuvant Stage II/III disease (T-DXd x4 followed by THP x4), and adjuvant treatment for residual invasive disease after neoadjuvant HER2-targeted therapy.
The data are striking. DESTINY-Breast11: pCR 67.3% vs 56.3% with ddAC-THP (p=0.003). DESTINY-Breast05: 3-year IDFS 92.4% vs 83.7% with T-DM1, HR 0.47 (95% CI 0.34-0.66, p<0.0001).
But the real work is just beginning.
Not every high-risk patient needs T-DXd upfront. Our challenge as oncologists is figuring out who needs what. Biomarker-driven selection, ctDNA, pCR response – these questions have to follow. Escalation and de-escalation must evolve together.”
Other articles about Breast Cancer on OncoDaily.